![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Mylan Laboratories Limited Hyderabad In, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Fluticasone propionate, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R0-CEP 2014-134 - Rev 02
This Chemical Type CEP, issued on September 27, 2017, remains in force until December 06, 2019, ensuring its reliability within the pharmaceutical industry.
Substance Number 1750 associated with this CEP further emphasizes